{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:39:27Z","timestamp":1790617167698,"version":"4.1.0"},"reference-count":53,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2001,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There are continuing concerns over the safety of the nation's and the world's blood supply. The allogeneic blood supply is tested for antibodies to HIV1\/2, HTLVI\/II, hepatitis B, hepatitis C (HCV) and syphilis. Testing is also performed for donor ALT (SGOT) levels, for the presence of hepatitis B surface antigen, human immunodeficiency virus (HIV) p24 antigen and, using nucleic acid amplification testing (NAT), for HIV and HCV nucleic acids. Still, there are concerns regarding other pathogenic agents.<\/jats:p><jats:p>Dr. Roger Dodd addresses a series of pathogens that are already known to be transmissible by transfusion. These include malaria, Chagas' disease, babesiosis, bacteria and some viral agents. The need for new donor screening assays to protect the integrity and purity of the blood supply must be balanced against the loss of potential donors and the cost of developing and implementing these new screening assays. This issue will be highlighted.<\/jats:p><jats:p>Dr. Edward Snyder reviews the status of research into development of systems for pathogen inactivation (PI) of blood and its components. A proactive technology wherein PI reagents such as psoralen, riboflavin, dimethylmethylene blue or inactine are added to blood collection bags could assure multiple log reduction of a variety of pathogens including viruses, bacteria, protozoa and fungi without the need to initially pre-screen the blood for a specific pathogen. Such a program could also cover new pathogens as they enter the blood supply. As a key issue relates to the toxicology of these agents, Dr. Snyder provides data on a novel carcinogenicity assay that uses a heterozygous p53 knock-out mouse model. The criteria likely to be needed for PI technology to be adopted by the transfusion community are summarized.<\/jats:p>","DOI":"10.1182\/asheducation-2001.1.433","type":"journal-article","created":{"date-parts":[[2003,8,28]],"date-time":"2003-08-28T00:29:50Z","timestamp":1062030590000},"page":"433-442","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":30,"title":["Reducing the Risk of Blood Transfusion"],"prefix":"10.1182","volume":"2001","author":[{"given":"Edward L.","family":"Snyder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger Y.","family":"Dodd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021223404740600_R1","doi-asserted-by":"crossref","unstructured":"Dodd RY. Germs, gels, and genomes: A personal recollection of 30 years in blood safety testing. In: Stramer SL, ed. Blood Safety in the New Millennium. Bethesda: American Association of Blood Banks; 2001:97-122.","DOI":"10.1007\/978-1-4757-6869-5_1"},{"key":"2020021223404740600_R2","doi-asserted-by":"crossref","unstructured":"Stramer SL, Caglioti S, Strong DM. NAT of the United States and Canadian blood supply. Transfusion. 2000;40:1165\u20131168.","DOI":"10.1046\/j.1537-2995.2000.40101165.x"},{"key":"2020021223404740600_R3","doi-asserted-by":"crossref","unstructured":"Nahlen BL, Lobel HO, Cannon SE, Campbell CC. Reassessment of blood donor selection criteria for United States travellers to malarious areas. Transfusion. 1991;31:798\u2013804.","DOI":"10.1046\/j.1537-2995.1991.31992094665.x"},{"key":"2020021223404740600_R4","doi-asserted-by":"crossref","unstructured":"Mungai M, Tegtmeier G, Chamberland M, Parise M. Transfusion-transmitted malaria in the United States from 1963 through 1999. N Engl J Med2001;344:1973\u20138","DOI":"10.1056\/NEJM200106283442603"},{"key":"2020021223404740600_R5","doi-asserted-by":"crossref","unstructured":"Schmun\u0303is GA. Trypanosoma cruzi, the etiologic agent of Chagas' disease: Status in the blood supply in endemic and nonendemic countries. Transfusion. 1991;31:547\u2013557.","DOI":"10.1046\/j.1537-2995.1991.31691306255.x"},{"key":"2020021223404740600_R6","doi-asserted-by":"crossref","unstructured":"Leiby DA, Read EJ, Lenes BA, et al. Seroepidemiology of Trypanosoma cruzi, etiologic agent of Chagas' disease, in US blood donors. J Infect Dis. 1997;176:1047\u20131052.","DOI":"10.1086\/516534"},{"key":"2020021223404740600_R7","doi-asserted-by":"crossref","unstructured":"Leiby DA, Fucci MH, Stumpf RJ. Trypanosoma cruzi in a low- to moderate-risk blood donor population: seroprevalence and possible congenital transmission. Transfusion. 1999;39:310\u2013315.","DOI":"10.1046\/j.1537-2995.1999.39399219290.x"},{"key":"2020021223404740600_R8","doi-asserted-by":"crossref","unstructured":"Leiby DA, Rentas FJ, Nelson KE, et al. Evidence of Trypanosoma cruzi infection (Chagas' disease) among patients undergoing cardiac surgery. Circulation. 2000;102:2978\u20132982.","DOI":"10.1161\/01.CIR.102.24.2978"},{"key":"2020021223404740600_R9","doi-asserted-by":"crossref","unstructured":"McQuiston JH, Childs JE, Chamberland ME, Tabor E. Transmission of tick-borne agents of disease by blood transfusion: a review of known and potential risks in the United States. Transfusion. 2000;40:274\u2013284.","DOI":"10.1046\/j.1537-2995.2000.40030274.x"},{"key":"2020021223404740600_R10","doi-asserted-by":"crossref","unstructured":"Eskow ES, Krause PJ, Spielman A, Freeman K, Aslanzadeh J. Southern extension of the range of human babesiosis in the eastern United States. J Clin Microbiol. 1999;37:2051\u20132052.","DOI":"10.1128\/JCM.37.6.2051-2052.1999"},{"key":"2020021223404740600_R11","doi-asserted-by":"crossref","unstructured":"Herwaldt BL, Kjemtrup AM, Conrad PA, et al. Transfusion-transmitted babesiosis in Washington state: First reported case caused by a WA1-type parasite. J Infect Dis. 1997;175:1259\u20131262.","DOI":"10.1086\/593812"},{"key":"2020021223404740600_R12","doi-asserted-by":"crossref","unstructured":"Saito-Ito A, Tsuji M, Wei Q, et al. Transfusion-acquired, autochthonous human babesiosis in Japan: Isolation of Babesia microti-like parasites with hu-RBC-SCID mice. J Clin Microbiol. 2000;38:4511\u20134516.","DOI":"10.1128\/JCM.38.12.4511-4516.2000"},{"key":"2020021223404740600_R13","doi-asserted-by":"crossref","unstructured":"Nash D, Mostashari F, Fine A, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med. 2001;344:1807\u201314.","DOI":"10.1056\/NEJM200106143442401"},{"key":"2020021223404740600_R14","doi-asserted-by":"crossref","unstructured":"Farge D, Lebbe\u0301 C, Marjanovic Z, et al. Human herpes virus-8 and other risk factors for Kaposi's sarcoma in kidney transplant recipients. Transplantation. 1999;67:1236\u20131242.","DOI":"10.1097\/00007890-199905150-00007"},{"key":"2020021223404740600_R15","doi-asserted-by":"crossref","unstructured":"Operskalski EA, Busch MP, Mosley JW, Kedes DH. Blood donations and viruses. Lancet. 1997;349:1327.","DOI":"10.1016\/S0140-6736(05)62544-5"},{"key":"2020021223404740600_R16","doi-asserted-by":"crossref","unstructured":"Cannon MJ, Dollard SC, Smith DK, et al. Blood-borne and sexual transmission of human herpesvirus 8 in women with or at risk for human immunodeficiency virus infection. N Engl J Med. 2001;344:637\u2013643.","DOI":"10.1056\/NEJM200103013440904"},{"key":"2020021223404740600_R17","doi-asserted-by":"crossref","unstructured":"Alter HJ, Nakatsuji Y, Melpolder J, et al. The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. N Engl J Med. 1997;336:747\u2013754.","DOI":"10.1056\/NEJM199703133361102"},{"key":"2020021223404740600_R18","doi-asserted-by":"crossref","unstructured":"Mushahwar IK. Recently discovered blood-borne viruses: Are they hepatitis viruses or merely endosymbionts? Commentary. J Med Virol. 2000;62:399\u2013404.","DOI":"10.1002\/1096-9071(200012)62:4<399::AID-JMV1>3.0.CO;2-U"},{"key":"2020021223404740600_R19","unstructured":"Orton SL, ARCNET Program, Liu H, Cable R, Grindon A, Williams A. Prevalence of circulating T. pallidum in STS+\/FTA-ABS+ blood donors [abstract]. Transfusion. 2000;39:2S."},{"key":"2020021223404740600_R20","unstructured":"Eastlund T, Persing D, Mathiesen D, et al. Human granulocytic ehrlichosis after red cell transfusion [abstract]. Transfusion. 2000;39:117S."},{"key":"2020021223404740600_R21","doi-asserted-by":"crossref","unstructured":"Wagner SJ, Friedman LI, Dodd RY. Transfusion-associated bacterial sepsis. Clin Microbiol Rev. 1994;7:290\u2013302.","DOI":"10.1128\/CMR.7.3.290"},{"key":"2020021223404740600_R22","doi-asserted-by":"crossref","unstructured":"Schreiber GB, Busch MP, Kleinman S, et al. The risk of transfusion-transmitted viral infections. N Engl J Med. 1996;334-1685-90.","DOI":"10.1056\/NEJM199606273342601"},{"key":"2020021223404740600_R23","doi-asserted-by":"crossref","unstructured":"Corash L. Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates: current research perspectives. Transfusion Med Rev. 1999;13:18\u201330.","DOI":"10.1016\/S0887-7963(99)80085-6"},{"key":"2020021223404740600_R24","doi-asserted-by":"crossref","unstructured":"Klein HG, Dodd RY, Dzik WH, et al. Current status of solvent\/detergent-treated frozen plasma. Transfusion. 1998;38:102\u2013107.","DOI":"10.1046\/j.1537-2995.1998.38198141508.x"},{"key":"2020021223404740600_R25","unstructured":"Mast AE, Latham K, Stadanlik, JE, et al. Solvent-detergent treatment of fresh frozen plasma causes polymerization and inactivation of antiplasmin but not antithrombin. Blood. 1998;92 (suppl. 1):502a. Abstract #2067."},{"key":"2020021223404740600_R26","doi-asserted-by":"crossref","unstructured":"Pehta JC: Clinical studies with solvent detergent-treated products. Transfusion Med Rev. 1996;10:303\u201311.","DOI":"10.1016\/S0887-7963(96)80006-X"},{"key":"2020021223404740600_R27","doi-asserted-by":"crossref","unstructured":"Lerner RG, Nelson J, Sorcia E, et al. Evaluation of solvent\/detergent-treated plasma in patients with a prolonged prothrombin time. Vox Sang. 2000;79:161\u20137.","DOI":"10.1046\/j.1423-0410.2000.7930161.x"},{"key":"2020021223404740600_R28","doi-asserted-by":"crossref","unstructured":"Evans G, Llewelyn C, Luddington R, Baglin TP, Williamson LM. Solvent\/detergent fresh frozen plasma as primary treatment of acute thrombotic thrombocytopenic purpura. Clin Lab Haematol. 1999;21:119\u201323","DOI":"10.1046\/j.1365-2257.1999.00191.x"},{"key":"2020021223404740600_R29","doi-asserted-by":"crossref","unstructured":"Tocci LJ, Napychank PA, Cable RG, Snyder EL. The effect of solvent\/detergent-treated plasma on stored platelet concentrates. Transfusion. 1993;33:145\u20139.","DOI":"10.1046\/j.1537-2995.1993.33293158047.x"},{"key":"2020021223404740600_R30","doi-asserted-by":"crossref","unstructured":"Geiger TL, Pisciotto PT, Baril LL, Snyder EL. The effect of solvent\/detergent-treated plasma on red cells stored in vitro. Transfusion. 1995;35:487\u201392.","DOI":"10.1046\/j.1537-2995.1995.35695288767.x"},{"key":"2020021223404740600_R31","unstructured":"Wages D, Smith D, Walsh J, et al. Transfusion of therapeutic doses of virally inactivated fresh frozen plasma in healthy subjects. Blood. 1997;90 suppl. 1:S1818"},{"key":"2020021223404740600_R32","unstructured":"Wages, D, Radu-Radurescu L, Adams M, et al. Quantitative analysis of coagulation factors in response to transfusion of S-59 photochemically treated fresh frozen plasma (S-59 FFP) and standard FFP. Blood. 1998;92 (suppl.1):503a."},{"key":"2020021223404740600_R33","doi-asserted-by":"crossref","unstructured":"Lin L, Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion. 1997;37:423\u201335.","DOI":"10.1046\/j.1537-2995.1997.37497265344.x"},{"key":"2020021223404740600_R34","doi-asserted-by":"crossref","unstructured":"Margolis-Nunno H, Bardossy L, Robinson R, et al. Psoralen-mediated photochemical decontamination of platelet concentrates: Inactivation of cell-free and cell-associated forms of human immunodeficiency virus and assessment of platelet function in vivo. Transfusion. 1997;37:889\u2013895.","DOI":"10.1046\/j.1537-2995.1997.37997454013.x"},{"key":"2020021223404740600_R35","doi-asserted-by":"crossref","unstructured":"Lin L, Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion. 1997;37:423\u2013435.","DOI":"10.1046\/j.1537-2995.1997.37497265344.x"},{"key":"2020021223404740600_R36","unstructured":"Lin L, Corten, L, Murthy KK, Corash L, et al. Photochemical inactivation of Hepatitis B (HBV) and Hepatitis C (HCV) virus in human platelet concentrates as assessed by a chimpanzee infectivity model. Blood. 1998;92 suppl. 1:502a."},{"key":"2020021223404740600_R37","unstructured":"Corash L, Behrman M, Rheinschmidt M, et al. Post-transfusion viability and tolerability of photochemically treated platelet concentrates (PC). Blood. 1997;90 Suppl. 1:S1171."},{"key":"2020021223404740600_R38","doi-asserted-by":"crossref","unstructured":"van Rhenen DJ, Vermeij J. Mayaudon V, Hind C, Lin L, Corash L. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sang. 2000;79:206\u2013214","DOI":"10.1046\/j.1423-0410.2000.7940206.x"},{"key":"2020021223404740600_R39","unstructured":"van Rhenen DJ, Gulliksson H, Pamphilon D, et al. Helinx - Photochemically treated platelets are safe and effective for support of thrombocytopenia: results of the Eurosprite Phase 3 trial. Blood. 2000;96:Suppl 1:Abstract #3539."},{"key":"2020021223404740600_R40","unstructured":"McBurney LL, Goodrich TB, Hansen ET. The use of riboflavin for the viral inactivation of platelets. Transfusion. 2000;40 Suppl:37S. Abstract S136-0401."},{"key":"2020021223404740600_R41","unstructured":"Tay-Goodrich BH, Schuyler RJ, Goodrich RP, Dumont LJ. Evaluation of in vivo survival of photochemically treated platelet concentrates in non-human primates. Transfusion. 2000;40: Suppl;38S. Abstract S140-0401."},{"key":"2020021223404740600_R42","unstructured":"Cook D, Stassinopoulos A, Wollowitz S, et al. In vivo analysis of packed red blood cells treated with S-303 to inactivate pathogens. Blood. 1998;92:(suppl. 1) 503a."},{"key":"2020021223404740600_R43","unstructured":"Cook D, Stassinopoulos A, Merrit J, et al. Inactivation of pathogens in packed red blood cell (PRBC) concentrates using S-303. Blood. 1997;90:(Suppl. 1):S1820"},{"key":"2020021223404740600_R44","doi-asserted-by":"crossref","unstructured":"Wagner SJ, Skripchenko A, Robinette D, et al. Preservation of red cell properties after virucidal phototreatment with dimethylmethylene blue. Transfusion. 1998;38:729\u201337.","DOI":"10.1046\/j.1537-2995.1998.38898375511.x"},{"key":"2020021223404740600_R45","doi-asserted-by":"crossref","unstructured":"Skripchenko A, Wagner SJ. Identification of the target responsible for M13 virus inactivation by dimethylmethylene blue and light treatment. Transfusion. 2000;40 Suppl:37S. Abstract S138-0401.","DOI":"10.1046\/j.1537-2995.2000.40080968.x"},{"key":"2020021223404740600_R46","doi-asserted-by":"crossref","unstructured":"Skripchenko A, Wagner SJ. Inactivation of WBCs in RBC suspensions by photoactive phenothiazine dyes: comparison of dimethylmethylene blue and MB. Transfusion. 2000;40:968\u201375","DOI":"10.1046\/j.1537-2995.2000.40080968.x"},{"key":"2020021223404740600_R47","doi-asserted-by":"crossref","unstructured":"Chapman J. Progress in improving the pathogen safety of red cell concentrates. Vox Sang. 2000;78 (Suppl 2):203\u20134.","DOI":"10.1046\/j.1423-0410.2000.78302004.x"},{"key":"2020021223404740600_R48","unstructured":"Aubuchon JP, Pickard CA, Herschel LH, et al. In vivo recovery of red blood cells virally inactivated by Inactine and stored for 28 days. Blood 2000:96 Suppl 1:Abstract 3538:818a."},{"key":"2020021223404740600_R49","unstructured":"Edson C, Purmal A, Zhang Q-X, Budowsky E. Inactine \u2013 a viral inactivation technology for reducing the infectivity of plasma-derived proteins. Transfusion. 1998;38 Suppl 1: Abstract S277;75S."},{"key":"2020021223404740600_R50","unstructured":"Zhang Q-X, Edson C, Budowsky E, Purmal A. Inactine \u2013 a method for viral inactivation in red blood cell concentrate. Transfusion. 1998;38 Suppl 1: Abstract S279;75S"},{"key":"2020021223404740600_R51","unstructured":"Purmal A, Zhang Q-X, Edson C. Inactine \u2013 a method to inactivate non-enveloped and enveloped viruses in red blood cell concentrates. Blood. 1998;92 Suppl 1: Abstract 3558; 136b."},{"key":"2020021223404740600_R52","doi-asserted-by":"crossref","unstructured":"Belanger KJ, Kelly DJ, Mettille C, et al. Psoralen photochemical inactivation of Orientia tsutsugamushi in platelet concentrates. Transfusion. 2000;40:1503\u20137.","DOI":"10.1046\/j.1537-2995.2000.40121503.x"},{"key":"2020021223404740600_R53","unstructured":"America's Blood Centers. Canadian animal handlers infected with animal Simian Foamy Virus; cautioned against blood donation. ABC Newsletter. 2001;26:8-10. June 29, 2001."}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2001\/1\/433\/1712919\/433.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2001\/1\/433\/1712919\/433.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T21:01:16Z","timestamp":1682542876000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2001\/1\/433\/18614\/Reducing-the-Risk-of-Blood-Transfusion"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2001.1.433","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,1,1]]}}}